Thymidylate synthase gene polymorphisms effecting 5-FU response in breast cancer patients

Cancer Biomarkers

Volumn 6, Issue 2, 2009, Pages 83-93

  Kumar, Kalyana ^a   Vamsy, Mohana ^a   Jamil, Kaiser ^a  

^a Indo American Cancer Institute and Research Centre   (India)

Author keywords

ADRs: Adverse Drug Reaction; BC: Breast cancer; TYMS: Thymidylate Synthase

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; THYMIDYLATE SYNTHASE;

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; ENHANCER REGION; FEMALE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ENHANCER ELEMENTS, GENETIC; FEMALE; FLUOROURACIL; HUMANS; MENOPAUSE; POLYMORPHISM, SINGLE NUCLEOTIDE; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 77954110922     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2009-0121     Document Type: Article

References (25)

1. B.P. Andrew, E.W. Muller, J. Haasjes, R. Meinsma, L. Zoetekouw, H.R. Waterham, F. Baas, D.J. Richel and A.H. van Gennip, Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G > A mutation causing DPD deficiency, Clin Cancer Res 7 (2001), 1149-1153.
2. L. Sharp, J. Little, A.C. Schofield, E. Pavlidou, S.C. Cotton, Z. Miedzybrodzka, J.O. Baird, N.E. Haites, S.D. Heys and D.A. Grubb, Folate and breast cancer: the role of polymorphisms in methylenetetrahydrofolate reductase (MTHFR), Cancer Lett 181 (2002), 65-71.
3. T. Lecomte, J.-M. Ferraz and F. Zinzindohoúe, Thymidylate Synthase Gene Polymorphism Predicts Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy, Clinical Cancer Research 10 (2004), 5880-5888.
4. C.M. Ulrich, J. Bigler, C.M. Velicer, E.A. Greene, F.M. Farin and J.D. Potter, Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene, Cancer Epidemiol Biomarkers Prev 9 (2000), 1381-1385.
5. S. Kaneda, K. Takeishi, D. Ayusawa, K. Shimizu, T. Seno and S. Altman, Role in translation of a triple tandemly repeated sequence in the 5 -untranslated region of human thymidylate synthase mRNA, Nucleic Acids Res 15 (1987), 1259-1270.
6. N. Horie, H. Aiba, K. Oguro, H. Hojo and K. Takeishi, Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase, Cell Struct Funct 20 (1995), 191-197.
7. N. Horie and K. Takeishi, Identification of functional elements in the promoter region of the human gene for thymidylate synthase and nuclear factors that regulate the expression of the gene, J Biol Chem 272 (1997), 18375-18381.
8. S.T. Pullarkat, J. Stoehlmacher, V. Ghaderi, Y.P. Xiong, S.A. Ingles, A. Sherrod, R. Warren, D. Tsao-Wei, S. Groshen and H.J. Lenz, Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy, Pharmacogenomics J 1 (2001), 65-70.
9. R.V. Alluri, V. Mohan, S. Komandur, K. Chawda and J.R. Chaudhary, MTHFR C677T gene mutation as a risk factor for arterial stroke: a hospital based study, Eur J Neu 11 (2005), 1-5.
10. J. Chen, D.J. Hunter, M.J. Stampfer, C. Kyte, W. Chan, J.G. Wetmur, R. Mosig and J. Selhub, Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer, Cancer Epidemiol, Biomarkers Prev 12 (2003), 958-962.
11. M.C. Etienne, K. Ilc and J.L. Formento, Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity, Br J Cancer 90 (2004), 526-534.
12. K. Kawakami, D. Salonga, J.M. Park, K.D. Danenberg, H. Uetake, J. Brabender, K. Omura, G. Watanabe and P.V. Danenberg, Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression, Clin Cancer Res 7 (2001), 4096-4101.
13. Y. Shintani, M. Ohta, H. Hirabayashi, H. Tanaka, K. Iuchi, K. Nakagawa, H. Maeda, T. Kido, S. Miyosh and H. Matsuda, New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction, Int J Cancer 104 (2003), 790-795.
14. K. Kawakami, K. Omura, E. Kanehira and YWatanabe, Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers, Anticancer Res 19 (1999), 3249-3252.
15. X.J. Zhai, J. Gao, Z.B. Hu, J.H. Tang, J.W. Qin, S.Wang, X.C. Wang, G.F. Jin, J.Y. Liu, W.S. Chen, F. Chen, X.R. Wang, Q.Y. Wei and H.B. Shen, Polymorphisms in thymidylate synthase gene and susceptibility to breast cancer in a Chinese population: a case-control analysis, BMC Cancer 6 (2006), 138.
16. H.R. Luo, X.M. Lu, Y.G. Yao, N. Horie, K. Takeishi, L.B. Jorde and Y.P. Zhang, Length polymorphism of thymidylate synthase regulatory region in Chinese populations and evolution of the novel alleles, Biochem Genet 40 (2002), 41-51.
17. M.C. Etienne et al., Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses, J Clin Oncol 20 (2002), 2832-2843.
18. M.C. Etienne, K.L. Formento et al., Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity, Br J Cancer 90 (2004), 526-534.
19. D. Emma, M. Cuatrecases, M. Martinez-Iniesta, M. Navarro, F. Vilardell, E. Guino, L. Pareja, A. Figueras, D.G. Mollevi, T. Serrano, J. de Oca, M.A. Peinado, V. Moreno, J.R. Germa, G. Capella and A. Villanueva, Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment, J Clin Oncol 24 (2006), 1503-1611.
20. Z.-H. Huang, The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil - based adjuvant chemotherapy in Chinese population, Cancer Chemotherapy and Pharmacology 63 (2008).
21. R.L. Moreira and A. Almeida Schenka, Correlation between thymidylate synthase protein expression and gene polymorphism with clinicopathological parameters in colorectal carcinoma, International Journal of Surgical Pathology 17 (2009), 181.
22. T. Tsuji, S. Hidaka, T. Sawai et al., Polymorphism in the thymidylate synthase promoter enhancer region is not an ef- ficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer, Clin Cancer Res 9 (2003), 3700-3704.
23. J. Salgadoi, Natalia Zabalegu Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer, Oncology Reports 17 (2007), 325-328
24. A. Ruzzo, F. Graziano and F. Loupakis, Role of Pharmacogenetics as Predictive Biomarkers of Response and/or Toxicity in the Treatment of Colorectal Cancer Clin Colorectal Cancer 8 (2009), 15-21.
25. E. Villafranca, Y. Okruzhnov, M.A. Dominguez et al., Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer, J Clin Oncol 19 (2001), 1779-1786.